Malignant hyperthermia safety - A nationwide survey of publicly funded Swedish healthcare.
dantrolene
malignant hyperthermia
patient safety
Journal
Acta anaesthesiologica Scandinavica
ISSN: 1399-6576
Titre abrégé: Acta Anaesthesiol Scand
Pays: England
ID NLM: 0370270
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
revised:
11
03
2024
received:
19
11
2023
accepted:
16
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
3
4
2024
Statut:
aheadofprint
Résumé
Malignant hyperthermia (MH) is a rare pharmacogenetic disorder that can lead to a life-threatening reaction during general anaesthesia with triggering agents. Prompt life-saving treatment includes the immediate administration of the antidote dantrolene. This study investigated Swedish healthcare providers' awareness and adherence to guidelines and recommendations with respect to MH and whether adherence to safe MH-praxis varies with hospital care-complexity level and private versus public management form. Agreements and procurement specifications between all 21 Swedish County Councils and privately run surgical care providers were reviewed alongside with questionnaire-aided collection of information from 62 publicly funded health care providers (both privately and publicly run). No procurement requirement specification or contract contained requirements on anaesthesia or aspects of MH. All publicly run hospitals stocked dantrolene and 28 out of 52 (54%) stocked the recommended amount. Seven out of nine (78%) of the privately run institutions stocked dantrolene, and one stocked the recommended amount. Publicly run hospitals adhered to recommendations to a greater extent than privately run institutions, both with respect to stocking of dantrolene (p = .02) and to stocking the recommended amount (p = .03). Contracts between Swedish county councils and private surgical care subcontractors rarely outline expectations of standards for the safe practice of anaesthesia such as preparedness to handle a life-threatening MH reaction. Among Swedish publicly funded anaesthesia providers there is room for improvement in adherence to the EMHG guideline on dantrolene availability. Publicly run hospitals seem to have better compliance with these recommendations than privately run institutions. Raising awareness about current guidelines is important to improve safety for known and unknown MH-susceptible individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant hyperthermia (MH) is a rare pharmacogenetic disorder that can lead to a life-threatening reaction during general anaesthesia with triggering agents. Prompt life-saving treatment includes the immediate administration of the antidote dantrolene. This study investigated Swedish healthcare providers' awareness and adherence to guidelines and recommendations with respect to MH and whether adherence to safe MH-praxis varies with hospital care-complexity level and private versus public management form.
METHOD
METHODS
Agreements and procurement specifications between all 21 Swedish County Councils and privately run surgical care providers were reviewed alongside with questionnaire-aided collection of information from 62 publicly funded health care providers (both privately and publicly run).
RESULTS
RESULTS
No procurement requirement specification or contract contained requirements on anaesthesia or aspects of MH. All publicly run hospitals stocked dantrolene and 28 out of 52 (54%) stocked the recommended amount. Seven out of nine (78%) of the privately run institutions stocked dantrolene, and one stocked the recommended amount. Publicly run hospitals adhered to recommendations to a greater extent than privately run institutions, both with respect to stocking of dantrolene (p = .02) and to stocking the recommended amount (p = .03).
CONCLUSIONS
CONCLUSIONS
Contracts between Swedish county councils and private surgical care subcontractors rarely outline expectations of standards for the safe practice of anaesthesia such as preparedness to handle a life-threatening MH reaction. Among Swedish publicly funded anaesthesia providers there is room for improvement in adherence to the EMHG guideline on dantrolene availability. Publicly run hospitals seem to have better compliance with these recommendations than privately run institutions. Raising awareness about current guidelines is important to improve safety for known and unknown MH-susceptible individuals.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Anna och Edwin Bergers Stiftelse
Informations de copyright
© 2024 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.
Références
Denborough M. Malignant hyperthermia. Lancet. 1998;352(9134):1131‐1136.
Gonsalves SG, Ng D, Johnston JJ, et al. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology. 2013;119(5):1043‐1053.
Monnier N, Kozak‐Ribbens G, Krivosic‐Horber R, et al. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat. 2005;26(5):413‐425.
Ibarra MC, Wu S, Murayama K, et al. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006;104(6):1146‐1154.
Mungunsukh O, Deuster P, Muldoon S, O'Connor F, Sambuughin N. Estimating prevalence of malignant hyperthermia susceptibility through population genomics data. Br J Anaesth. 2019;123(3):e461‐e463.
Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970;17(4):293‐315.
Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001–2005. Anesth Analg. 2009;109(4):1162‐1166.
Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985;64(7):700‐704.
Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110(1):89‐94.
Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105(4):417‐420.
Rüffert H, Bastian B, Bendixen D, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126(1):120‐130.
Glahn KPE, Bendixen D, Girard T, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125(2):133‐140.
Malignant Hyperthermia Association of the United States. How Much Dantrolene Should be Available in Facilities Where Volatile Agents are not Available or Administered, and Succinylcholine is Only Stocked on Site for Emergency Purposes? MHAUS. 2018 https://www.mhaus.org/healthcare‐professionals/mhaus‐recommendations/how‐much‐dantrolene‐should‐be‐available‐in‐facilities‐where‐volatile‐agents‐are‐not‐available‐or‐administered‐and‐succinylcholine‐is‐only‐stocked‐on‐site‐for‐emergency‐purposes/#_ftn1
Socialstyrelsen. Ovanliga hälsotillstånd – Malign hypertermikänslighet: Socialstyrelsen. 2017 https://www.socialstyrelsen.se/kunskapsstod-och-regler/omraden/sallsynta-halsotillstand/malign-hypertermikanslighet/
Socialstyrelsen. About the Swedish healthcare system: Socialstyrelsen. 2020 https://www.socialstyrelsen.se/en/about-us/healthcare-for-visitors-to-sweden/about-the-swedish-healthcare-system/
Upphandlingsmyndigheten. Upphandla eller utkontraktera vård och omsorg: Upphandlingsmyndigheten. 2024 https://www.upphandlingsmyndigheten.se/branscher/vard‐och‐omsorg/#upphandla_eller_infora_valfrihetssystem
Inspektionen för Vård och Omsorg. Notification of activities under the patient safety act. IVO. 2023; https://www.ivo.se/other-languages/report-activities/healthcare-provider-register/
Aderibigbe T, Lang BH, Rosenberg H, Chen Q, Li G. Cost‐effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia. Anesthesiology. 2014;120(6):1333‐1338.
Swedish National Society of Anaesthesia and Intensive Care (SFAI). SFAIs Utbildningsbok enligt HSLF. 2021 https://sfai.se/utbildning/st-utbildning/utbildningsbocker/utbildningsbok-enligt-hslf-fs-20218/2021